Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb 5:10:93-103.
doi: 10.2147/CEOR.S150900. eCollection 2018.

Oral versus intravenous iron therapy in patients with inflammatory bowel disease and iron deficiency with and without anemia in Germany - a real-world evidence analysis

Jürgen Stein  1   2 , Jennifer Scarlet Haas  3 , Siew Hwa Ong  4 , Kathrin Borchert  3 , Thomas Hardt  5 , Elmira Lechat  4 , Kerry Nip  5 , Douglas Foerster  4 , Sebastian Braun  3 , Daniel C Baumgart  6
Affiliations

Oral versus intravenous iron therapy in patients with inflammatory bowel disease and iron deficiency with and without anemia in Germany - a real-world evidence analysis

Jürgen Stein et al. Clinicoecon Outcomes Res. .

Abstract

Background: Iron-deficiency anemia and iron deficiency are common comorbidities associated with inflammatory bowel disease (IBD) resulting in impaired quality of life and high health care costs. Intravenous iron has shown clinical benefit compared to oral iron therapy.

Aim: This study aimed to compare health care outcomes and costs after oral vs intravenous iron treatment for IBD patients with iron deficiency or iron deficiency anemia (ID/A) in Germany.

Methods: IBD patients with ID/A were identified by ICD-10-GM codes and newly commenced iron treatment via ATC codes in 2013 within the InGef (formerly Health Risk Institute) research claims database. Propensity score matching was performed to balance both treatment groups. Non-observable covariates were adjusted by applying the difference-in-differences (DID) approach.

Results: In 2013, 589 IBD patients with ID/A began oral and 442 intravenous iron treatment. After matching, 380 patients in each treatment group were analyzed. The intravenous group had fewer all-cause hospitalizations (37% vs 48%) and ID/A-related hospitalizations (5% vs 14%) than the oral iron group. The 1-year preobservation period comparison revealed significant health care cost differences between both groups. After adjusting for cost differences by DID method, total health care cost savings in the intravenous iron group were calculated to be €367. While higher expenditure for medication (€1,876) was observed in the intravenous iron group, the inpatient setting achieved most cost savings (€1,887).

Conclusion: IBD patients receiving intravenous iron were less frequently hospitalized and incurred lower total health care costs compared to patients receiving oral iron. Higher expenditures for pharmaceuticals were compensated by cost savings in other domains.

Keywords: Germany; claims data; health care cost; inflammatory bowel disease; iron treatment; iron-deficiency anemia.

PubMed Disclaimer

Conflict of interest statement

Disclosure SHO, TH, EL, KN, and DF are employees of and hold stock/stock options in Vifor Pharma. JS and DCB have received reimbursements for participation in the scientific advisory council for this study from Vifor Pharma. JS has received lecturing fees from Vifor Pharma. JSH, KB, and SB are employees of Xcenda, which has a research consultancy agreement with Vifor Pharma. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Study design. Abbreviations: IBD, inflammatory bowel disease; ID/A, iron deficiency/iron deficiency anemia; IV, intravenous.
Figure 2
Figure 2
Sample selection. Abbreviations: InGef, Institut für angewandte Gesundheitsforschung Berlin; IV, intravenous; ID/A, iron deficiency/iron deficiency anemia.
Figure 3
Figure 3
Health care cost during/after iron treatment. Note: *Statistically significant differences (p<0.05).
Figure 4
Figure 4
Difference-in-differences approach.
See this image and copyright information in PMC

References

    1. Camaschella C. Iron-deficiency anemia. N Engl J Med. 2015;372(19):1832–1843. - PubMed
    1. Blumenstein I, Dignass A, Vollmer S, Klemm W, Weber-Mangal S, Stein J. Current practice in the diagnosis and management of IBD-associated anaemia and iron deficiency in Germany: the German AnaemIBD Study. J Crohns Colitis. 2014;8(10):1308–1314. - PubMed
    1. Danese S, Hoffman C, Vel S, et al. Anaemia from a patient perspective in inflammatory bowel disease: results from the European Federation of Crohn’s and Ulcerative Colitis Association’s online survey. Eur J Gastroenterol Hepatol. 2014;26(12):1385–1391. - PubMed
    1. Rogler G, Vavricka S. Anemia in inflammatory bowel disease: an underestimated problem? Front Med. 2014;1:58. - PMC - PubMed
    1. Martin J, Radeke HH, Dignass A, Stein J. Current evaluation and management of anaemia in patients with inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2017;11(1):19–32. - PubMed